A process for preparing halogenated azaindole compounds makes use of stable reagents including a brominating reagent, a boroxine and a sulfonic anhydride to enhance the selectivity and yield of the final product. In addition, the process is associated with various other advantages, including the ability to recycle reagents, cost reduction, and improved manufacturability.

The present invention relates to a curing catalyst for an epoxy resin composition represented by chemical formula 1, an epoxy resin composition comprising the same, and an apparatus manufactured using the same.

According to one or more embodiments, an organic light-emitting device may include: a first electrode; a second electrode facing the first electrode, and an organic layer between the first electrode and the second electrode, the organic layer including an emission layer, wherein the organic layer includes an amine-based compound represented by Formula 1: ##STR00001##

Disclosed are a water-soluble fluorescent probe and nanoparticles with an aggregation induced emission (AIE) effect and preparation methods and the application. The fluorescent probe molecule includes one imidazole ring substituted by two methoxyphenyls and one phenyl and two quaternary ammonium salt structures. It has good dispersion in water, may form micelles. It has the characteristics of AIE effect and a large Stokes shift etc. It is suitable for fluorescence detection. Under the induction of lysophosphatidic acid, the probe can be self-assembled so as to aggregate and generate yellow fluorescence. Lysophosphatidic acid may be quantitatively analyzed by measuring the intensity of emitted fluorescence.

Substituted benzimidazole and 3H-imidazo[4,5-b]pyridines or formula I: where X and Y respectively are selected from: (i) N and N; and (ii) N and CR.sup.4; A.sup.2 is selected from: a C.sub.5 heteroarylene group, containing 2 or 3 ring heteroatoms, where the bonds to L1 and the core are to one another; L.sup.1 is selected from: (i) .sup.A1OCH.sub.2.sup.A2; (ii) .sup.A1CH.sub.2O.sup.A2; (iii) .sup.A1C(O)NH.sup.A2; (iv) .sup.A1CH(OH).sup.A2; (v) .sup.A1CH.sub.2NHC(O).sup.A2; (vi) .sup.A1SCH.sub.2.sup.A2; (vii) .sup.A1CH.sub.2S.sup.A2; (viii) .sup.A1CH.sub.2.sup.A2; and (ix) .sup.A1CH(CH.sub.3)O.sup.A2; A1 is phenyl, optionally substituted by F or CF.sub.3; their use as pharmaceuticals, and in particular, in treating cancer and hemoglobinopathies. ##STR00001##

The present invention provides a composition for controlling pests having an excellent control efficacy on pests. A composition for controlling pests comprising a compound represented by the formula (1): ##STR00001##
wherein each of symbols are the same as defined in the Description, or N-oxide thereof; and
a compound represented by the formula (2): ##STR00002##
wherein each of symbols are the same as defined in the Description;
shows an excellent controlling efficacy on pests.

The invention provides EBNA1 inhibitors, and pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The compounds and compositions of the invention are further useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. The compounds and compositions of the invention are further useful for the treatment of diseases caused by lytic EBV infection.

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

The invention relates to a new class of compounds, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions that are effective as selective inhibitors of factor Xa, both in the isolated state and in a complex with other proteins. The compounds of the invention can be used for treating and preventing diseases, such as acute coronary syndrome, myocardial infarction, unstable angina, refractory angina, thromboses caused by post-thrombolytic therapy or coronary angioplasty, acute ischemia mediated cerebrovascular syndrome, embolic stroke, thrombotic stroke, and other diseases in humans and other mammals associated with blood coagulation problems.